Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
about
Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approachesSPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases.Non-invasive metabolic imaging of brain tumours in the era of precision medicine.Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in GlioblastomaEffective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma.CNS Anticancer Drug Discovery and Development Conference White Paper.Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.Early prediction of treatment response in advanced gliomas with (18)F-dopa positron-emission tomographyTargeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.Amino acid PET and MR perfusion imaging in brain tumours.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.Anaplastic astrocytoma.Neurologic Applications of PET/MR Imaging.Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI.PET Molecular Imaging-Directed Biopsy: A Review.Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.The role of LAT1 in (18)F-DOPA uptake in malignant gliomas.Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool.Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp’s Trial: More Controversies than Standards?Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
P2860
Q30366921-AF14BC5E-50ED-44E4-9DD2-F2ED9FB22991Q30725125-4D883CAD-FC81-4936-A3AB-1D76255B0867Q30828977-96981B0C-2299-4650-B759-97500126399CQ31115540-B16D7516-F7AE-420C-93BF-46A2EBA77F77Q34348544-95151FA0-981E-493F-8733-E174EFFEED5DQ35463482-1BC9FEF1-6A37-45F3-89A2-A6C40EEF0E50Q35561280-F1E40555-4D42-4536-8CCF-8B99D74C1CB2Q35679377-D2B8162B-D9CA-4630-9E20-1FC14016E028Q35799917-F5628F7B-C9BF-47E1-BC02-D3CF9DF058C0Q35849699-80B236F3-0497-4592-A584-655367B0EABFQ36089590-F700C178-4283-453E-A33A-F96632B04EECQ36107368-B681C7A4-4F55-4A4D-8DE6-F0BAB8E780B7Q37037922-B32B9F2F-3477-40AD-ACE1-44CF8D9E033DQ37577677-DF4E4EB1-18EC-4997-8919-7735DFB6FD51Q38476583-5D560D8E-295A-4392-8500-8EDA15CA1001Q38691946-82451A1A-0192-43F9-B7E6-8C942BE2A6A9Q38815396-14127346-A3F9-4DD5-A6DA-65E91BC15385Q38829439-DC7AD4A5-382A-4FD5-84A1-4D7F6308DDF9Q38845657-56DF791A-1E9B-4416-B696-58CF284F413BQ38846608-42EFDBB9-24F6-4496-BFC7-2936506B19E2Q39031636-6415BA2B-8A86-4260-993A-FF634EADB2F6Q39306671-7BFD2A0D-8D2F-46CA-9A49-891419EB5DD8Q41635534-65269A9E-BB29-4079-A396-6A200AD2C2B5Q41900708-D91C0B6C-54D1-4239-9F8B-3839315890CCQ42022095-EE5F961E-B9E5-4B63-9EDE-62CB9B93FD2BQ45973213-C1234B18-496D-4759-AE2D-D0C26E70152DQ47734339-97A1730A-8ABB-4180-BE09-CE46C2DF3E82Q47827207-9428C020-6049-406B-8222-9EBB10B489BEQ47833074-2576B8C4-FE74-49B7-BF10-600285939AECQ52986869-4DDBCE88-1912-4C56-9509-B8E7B9D80739Q53098438-A2A79C11-F3CF-4504-BDD9-2E106D4ABDA2Q54135407-78CE2E2C-8C2C-4846-B5EB-5493FB476A5CQ55711736-3ED5422C-C7BC-4148-BF39-003FA923BA28Q59134092-FB039312-022D-4474-A44E-0E641FDBC279
P2860
Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Biopsy validation of 18F-DOPA ...... of a prospective pilot study.
@ast
Biopsy validation of 18F-DOPA ...... of a prospective pilot study.
@en
type
label
Biopsy validation of 18F-DOPA ...... of a prospective pilot study.
@ast
Biopsy validation of 18F-DOPA ...... of a prospective pilot study.
@en
prefLabel
Biopsy validation of 18F-DOPA ...... of a prospective pilot study.
@ast
Biopsy validation of 18F-DOPA ...... of a prospective pilot study.
@en
P2093
P2860
P921
P356
P1433
P1476
Biopsy validation of 18F-DOPA ...... s of a prospective pilot study
@en
P2093
Brad J Kemp
Caterina Giannini
Deanna H Pafundi
Debra H Brinkmann
Jann N Sarkaria
Jason M Hoover
Jonathan M Morris
Leland S Hu
Michael P Grams
Nadia N Laack
P2860
P304
P356
10.1093/NEUONC/NOT002
P577
2013-03-03T00:00:00Z